Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Phase 3TerminatedNCT00124930

Alberta Health services80 enrolled

Overview

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Nausea Neoplasms

Interventions

OlanzapineDRUG

HaldolDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>18 years of age * Significant nausea/vomiting * Failed maxeran and domperidone * Underlying treatment of causes has failed * Adequate cognitive function * Communicates well Exclusion Criteria: * Partial/complete bowel obstruction * Currently taking Haldol or olanzapine * Has drug induced extrapyramidal symptoms * Parkinson's disease * Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus

Locations (1)

Tom Baker Cancer Centre

Calgary, Alberta, Canada

Outcomes

Primary Outcomes

Severity of nausea on days 3 and 5

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.